With the presidential election less than two months away, we’re taking some time to see where the candidates stand on prescription drug access and affordability issues – and glance at the national positions of the Democratic and Republican parties. Drug prices are not a good issue for the candidates to ignore, as tens of millions of families across the nation are impacted. According to a study in the Journal of the American Medical Association, almost 60% of American adults took at least one prescription drug in 2012, with 15% taking five or more medications. Moreover, the cost of prescription drugs is their number one healthcare concern.
A 2015 poll by the Kaiser Family Foundation found that 76 percent of U.S. adults think that the top healthcare priority for the current Administration and Congress should be "making sure that high-cost drugs for chronic conditions, such as HIV, hepatitis, mental illness and cancer, are affordable to those who need them.” Recent headlines, such as those featuring the EpiPen price hike, further highlight the public’s outrage over the soaring cost of prescription medications.
Part of a series of posts about common chronic illnesses and what happens when people cannot afford prescription medications to treat them.
According to the Centers for Disease Control and Prevention, an estimated 29.1 million people, or 9.3% of the U.S. population, have diabetes. Left untreated, diabetes can lead to unnecessary hospitalizations and death. While Diabetes ranks as the seventh leading cause of death in the U.S., many people with diabetes actually die from complications related to diabetes rather than the disease itself. In 2011, 85.3% of adults with diagnosed diabetes reported taking pills or insulin for their diabetes. But, the increasing cost of diabetes medications in the U.S. often leads patients to forgo or ration life-saving treatments.
Pay-for-delay deals undermine the intent of the Hatch-Waxman Act, which was passed in 1984 to encourage generic drug companies to bring lower cost medications to market at the earliest – not the latest – point possible. A 2010 FTC report recommended that Congress pass legislation to protect consumers from such anticompetitive agreements. The FTC wrote: “a legislative solution offers the quickest and clearest way to deter these agreements and obtain the benefits of generic competitions form consumers. (more…)
A first in a series of posts about common chronic illnesses and what happens when people cannot afford prescription medications to treat them.
Asthma is a chronic lung disease very common in the United States and worldwide. The disease is characterized by a narrowing of the airways in the lungs that is treatable with various medications and avoiding environmental factors that trigger asthma attacks. When patients don’t take prescribed medications to treat their asthma the consequences can be deadly. The Centers for Disease Control and Prevention reports that in 2010 asthma accounted for 3,404 deaths, 439,400 hospitalizations, 1.8 million emergency room visits, and 14.2 million physician office visits. Drug costs are one of the main reasons people are not taking their asthma medications.